表皮生长因子受体抑制剂在非小细胞肺癌治疗中的研究进展  

Research progress on epidermal growth factor receptor inhibitors for non-small cell lung cancer therapy

作　　者：刘海涛[1] 陈余清[1] 

机构地区：[1]蚌埠医学院第一附属医院呼吸内科,233004

出　　处：《国际呼吸杂志》2012年第8期634-639,共6页International Journal of Respiration

基　　金：安徽省科技厅科技攻关项目（11010402169）

摘　　要：化疗一直是晚期非小细胞肺癌（NSCLC）的主要治疗手段之一，但是治疗的有效率仅为30％左右，且具有较大的不良反应，耐药和血液学的不良反应是患者预后不良的主要原因之一。随着分子生物标记如表皮生长因子受体（EGFR）等的发现和相应靶向药物的研发与批准应用，肺癌的治疗正在发生重大变化。大量研究证实EGFR抑制剂靶向治疗能改善NSCLC患者的疾病无进展期和生活质量，而正确的选择合适的患者是靶向治疗成功的关键。本文将对EGFR的组成及活化、检测方法、EGFR靶向药物在NSCLC治疗中的作用以及获得性耐药患者的治疗进展进行综述。Chemotherapy has always been one of the main methods in the treatment of advanced non-small cell lung cancer （NSCLC）. However, the total effective rate is only about 30% and it has a greater toxic side effects. Drug resistance and hematologic toxicity are one of the major reasons causing poor prognosis for chemotherapy. With the discovery of molecular biomarkers, such as epidermal growth factor receptor （EGFR）, and the research and development of relevant targeted medicine and its application, there are big changes taking place in the treatment of lung cancer. A great deal of study testify that EGFR inhihitors targeted therapy can improve the progression-free survival and the quality of life of NSCLC patients, and correctly choosing the appropriate patients is the key to get success in targeted therapy. This article summarizes the composition and activation of EGFR, its inspection methods, the effect of EGFR targeted medicine in the treatment of NSCLC and the progression in the treatment of acquired drug resistance patients.

关 键 词：非小细胞肺癌 表皮生长因子受体 吉非替尼 厄洛替尼 埃克替尼 西妥昔单抗 

分 类 号：R734.2[医药卫生—肿瘤]